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PATIENT OUTCOMES ASSOCIATED WITH BIOLOGIC INFUSION SITE OF CARE
FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Bolge S1, Ingham M1, Gupta S2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Kantar Health, Princeton, NJ, USA
OBJECTIVES: To assess the association of site of care (SOC) for rheumatoid arthritis
(RA) related biologic infusion with clinical outcomes, health status, work produc-
tivity loss, and healthcare resource use. METHODS: In 2009 and 2010, individuals
aged 18 and reporting an RA diagnosis completed a cross-sectional, self-admin-
istered, Internet-based questionnaire. SOC was categorized as currently receiving
infusions of abatacept, infliximab, rituximab, or tocilizumab: in a physician’s office
(IOI), a hospital outpatient department (HOPD), or other alternate sites of care
(ASOC). Clinical outcomes included the Health Assessment Questionnaire (HAQ)
and severity of morning stiffness, fatigue, and pain, measured as 1none experi-
enced to 10severe. Health status was assessed using the SF-36, and work produc-
tivity losswas assessed using theWork Productivity andActivity Impairment ques-
tionnaire. Healthcare resource use in the past six months included emergency
room visits, hospitalization, and physician visits. Patient demographics and co-
morbidities were adjusted using linear regression and negative binomial regres-
sion as appropriate. RESULTS: Of 273 infusion patients analyzed, 54.6% (n149)
were categorized as IOI, 11.7% (n32) HOPD, and 33.7% (n92) ASOC. IOI patients
were more likely to be female (80.5%) than HOPD and ASOC patients (50.0% and
65.2% respectively, p0.001).Other demographics and comorbidities were similar
across SOC categories. SOCwas not significantly associatedwith clinical outcomes,
health status, work productivity loss, or healthcare resource use with few excep-
tions. Compared to IOI patients, HOPD patients had poorer SF-36 role emotional
scores (b-13.54, p0.022) and ASOC patients had better vitality scores (b6.67,
p0.006). Also, ASOCpatients had fewer average visits to traditional providers than
IOI patients (p0.011). CONCLUSIONS: With few exceptions, clinical outcomes,
health status, work productivity loss, and healthcare resource use are similar re-
gardless of SOC for biologic infusion. Therefore, other factors may drive choice of
SOC, such as convenience for the patient and cost for the patient and payer.
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INFLIXIMAB INFUSION PATTERNS IN PATIENTS WITH RHEUMATOID
ARTHRITIS ‘NAÏVE’ TO BIOLOGIC THERAPY: AN ANALYSIS OF A NATIONAL
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OBJECTIVES: FDA prescribing information for infliximab (IFX) treatment of pa-
tients with rheumatoid arthritis (RA) recommends infusions at weeks 0, 2 and 6
followed by every 8 weeks, with a 4 week option. This study examines infusion
intervals in RA patients enrolled in a large United States health plan. METHODS:
Claims data were obtained from the i3Innovus database for October 2006 through
June 2009. Inclusion criteria were  2 diagnoses for RA (714.xx), absence of a diag-
nosis for selected anti-inflammatory disorders, age18,4 IFX infusions, absence
of any biologic claim for 6 months prior to index date, and  12 months of contin-
uous eligibility post-index. A treatment episode was defined as infusions from
index claim to the last IFX claim in the dataset without a claim for other biologics
during that episode. Patients with IFX infusions  180 days were excluded. The
samplemean at each infusionwas compared to prescribing information.RESULTS:
Of patients meeting inclusion criteria (N652), the number of infusions received
ranged from 4 to 48 (mean of 11). The mean interval (SD) between the first and
second infusionwas 20 days (17); 76%of the sample received their infusionwithin
three days of the recommended 14 days. The mean interval between the second
and third infusion was 33 days (12). The mean interval between each of the next
8 maintenance infusions ranged between 50 and 54 days (SDs ranging from 15-16
days), with a mean across all intervals of 51 days (7weeks). CONCLUSIONS: Data
from this national health plan indicate that induction and maintenance intervals
were consistent with the FDA recommended prescribing information. Physicians
in this particular health plan appeared to be administering IFX in accordance with
the FDA-approved administration schedule for RA.
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ASSOCIATION OF SATISFACTION WITH SUBCUTANEOUS ANTI-TNF THERAPY
AND CLINICAL OUTCOMES, HEALTH STATUS, AND LOST WORK
PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
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OBJECTIVES: To assess the association of satisfactionwith subcutaneous (SQ) anti-
TNF therapy and clinical outcomes, health status, and work productivity loss
among patients with rheumatoid arthritis (RA).METHODS: In 2009 and 2010, indi-
viduals aged 18 and reporting an RA diagnosis completed a cross-sectional, self-
administered, Internet-based questionnaire. Satisfactionwith current SQ anti-TNF
therapy (adalimumab, certolizumab, etanercept, and golimumab) was assessed on
a five-point Likert scale. Differences in outcomes were compared between patients
who were very satisfied (satisfaction4 or 5) and not very satisfied (satisfaction1,
2, or 3). Clinical outcomes included the Health Assessment Questionnaire (HAQ)
and severity of morning stiffness, fatigue, and pain, measured as 1none experi-
enced to 10severe. Health status was assessed using the SF-36, and work produc-
tivity losswas assessed using theWork Productivity andActivity Impairment ques-
tionnaire. Patient demographics and comorbidities were adjusted using linear
regression for clinical outcomes and health status and negative binomial regres-
sion for lost work productivity. RESULTS: Of 474 patients currently using SQ anti-
TNFs, 68.1% (n323) were very satisfied. After adjustment, greater satisfactionwas
associated with less functional disability (HAQ: regression coefficient b-0.21,
p0.001); less severity of morning stiffness (b-1.09, p0.001), less fatigue (b-
1.06, p0.001), and less pain (b-1.00, p0.001); and better health status (SF-36
physical component summary: b3.60, p0.001 andmental component summary:
b2.98, p0.005). Among the employed, greater satisfaction was associated with
less absenteeism (p0.059), less presenteeism (p0.007), and lower overall work
impairment (p0.020). CONCLUSIONS: Greater patient satisfaction with SQ anti-
TNF therapy is associated with better clinical outcomes and health status and
increased work productivity. However, due to the cross-sectional nature of the
study, the direction of these associations cannot be determined. Treatment attri-
butes that improve patient satisfaction may have additional benefits. Further re-
search is needed to investigate the potential impact of treatment attributes on
patient satisfaction and outcomes.
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SATISFACTION, PREFERENCE AND REASONS FOR BIOLOGIC TREATMENT
DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
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OBJECTIVES: To assess current patient unmet needs in rheumatoid arthritis (RA)
treatment by exploring patient experiences with biologics, including satisfaction,
preference, and reasons for non-adherence and discontinuation. METHODS: In
August 2009, 2,118 patients aged18 and self-reporting an RA diagnosis completed
a cross-sectional, self-administered, Internet-based questionnaire. Patients pro-
vided information about current and past use of biologic medication, treatment
satisfaction (satisfied defined as 4 or 5 on a 5-point scale from 1not at all satisfied
to 5extremely satisfied), preference for dosing frequency (less frequent dosing 
every month or less often and more frequent dosing  two or more doses per
month), adherence and reasons for non-adherence, and reasons for discontinua-
tion of biologic agents in the twelve months preceding the study. RESULTS: 571
(27%) patients had experience with biologic therapy. Of these, 45% were currently
using their first biologic, 29% had switched biologics and 27% used biologic therapy
anytime in the past, but since discontinued. Among current biologic users, 63%
were satisfied with their current therapy; however, among those who previously
switched or discontinued, only 56% and 50%, respectively, were satisfied with cur-
rent therapy. Of current biologic users, 72% preferred less frequent dosing of bio-
logic medication and 28% preferred more frequent dosing. Among patients who
stopped using a subcutaneous biologic in the year preceding the study (n62),
whether switching to another biologic or discontinuing altogether, reasons for
stopping included, doctors advice (42%), lack of efficacy (37%), side effects or infec-
tion (37%), medication cost (18%), and discomfort with administering (15%).
CONCLUSIONS: From the patient perspective, there are remaining unmet needs
related to efficacy and tolerability with biologic therapy. Furthermore, most pa-
tients showed preference for longer dosing intervals. Newer treatment options
may address some of these unmet needs. The patient perspective should be con-
sidered when making access decisions about newer biologic therapies.
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OBJECTIVES: To describe the experience of RA patients with subcutaneous (SC)
anti-TNF therapy from the patient perspective.METHODS: Patients aged 18 and
self-reporting an RA diagnosis completed a cross-sectional, self-administered, In-
ternet-based questionnaire inAugust 2009. Biologic therapies included in the ques-
tionnaire were abatacept, adalimumab, certolizumab, etanercept, golimumab, in-
fliximab and rituximab. This analysis focused on patients who reported current or
past use of adalimumab (ADA) or etanercept (ETA), themost commonly prescribed
SC anti-TNF agents. Certolizumab and golimumab were not included in the anal-
yses due to the limited time they were available at the time of the study and their
very small sample sizes. Patients provided information about their experiences
with self-injection and how these experiences have affected self-reported discon-
tinuation of therapy. RESULTS: A total of 263 patients were using SC anti-TNF
therapy (129 ADA and 134 ETA) at the time of the survey. More than half of SC
anti-TNF users (57%) experienced burning during or after injection. Of these, 15%
rated the burning as very or extremely intense and 56% rated the burning as some-
what intense. Among SC users who reported that they did not take their medica-
tion as directed all the time (n41), 12% cited discomfort in administering medi-
cation as often or very often a reason for treatment discontinuation. Of a small
group of patients reported discontinuing in the year preceding the study (n62),
lack of efficacy, side effects, cost of drugs, and discomfort in administering medi-
cation were cited as major reasons for discontinuation. CONCLUSIONS:More than
half of SC anti-TNF users experience burning during or after injection, and this
discomfort may adversely affect treatment discontinuation. The results suggest
that the patient experience should be considered when making treatment deci-
sions. Further research is needed to examine the relationship between injection
site reaction and patient outcomes including observed medication discontinua-
tion.
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